Viibryd Tablet
Product Images NDC 0456-1110

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Viibryd (NDC 0456-1110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Structural Formula For Vilazodone HCl Is 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-, Hydrochloride (1:1). Its Molecular Weight Is 477.99. (Viibryd 01)

Chemical structure of VIIBRYD (vilazodone) hydrochloride, showing the molecular arrangement including a cyanophenyl indole linked to a piperazine and benzofuran moiety with a hydrochloride salt.*

FDA Label Image

Figure 1. Effect Of Other Drugs On Vilazodone Pharmacokinetics (Viibryd 02)

A scatter plot with error bars illustrating pharmacokinetic changes relative to reference for VIIBRYD with various agents. The x-axis shows change relative to reference on a 0.5 to 2.0 scale. Data points represent Cmax and AUC changes for ethanol, CYP3A4 inhibitors (ketoconazole), CYP3A4 inducers (carbamazepine), and proton pump inhibitors (pantoprazole).*

FDA Label Image

Figure 2. Impact Of Vilazodone On Other Drug Pharmacokinetics (Viibryd 03)

A chart showing the fold change and 90% confidence interval of pharmacokinetic parameters for various CYP substrates and P-gp substrates. The x-axis represents the change relative to reference, ranging from 0.5 to 2.0. The chart includes data points for nifedipine, caffeine, debrisoquine, flurbiprofen, mephenytoin, and digoxin, with specific pharmacokinetic metrics like AUCp, CRmp, URmp, CLm, Um, Cmax, and AUC indicated.*

FDA Label Image

Figure 3: Impact Of Intrinsic Factors On Vilazodone Pharmacokinetics (Viibryd 04)

A chart depicting the pharmacokinetic fold change and 90% confidence intervals of VIIBRYD 10 mg, 20 mg, and 40 mg in different populations. It compares Cmax and AUC values for groups including age >65 years, gender (females), and degrees of renal and hepatic impairment (mild, moderate, severe), relative to reference subjects.*

FDA Label Image

Viibryd 05

FDA Label Image

Allergan Logo (Viibryd 06)

FDA Label Image

Ndc 0456-1110-30viibrydvilazodone Hcitablets30 Tablets10 mgrx Only (Viibryd 07)

Viibryd 10 mg tablets label showing the product name, active ingredient vilazodone HCl, strength of 10 mg per tablet, and quantity of 30 tablets. The label includes storage instructions, manufacturer Allergan USA, Inc., barcode, and regulatory information including the NDC 0456-1110-30 and Rx only status.*

FDA Label Image

Ndc 0456-1120-30viibrydvilazodone Hcitablets30 Tablets20 mgrx Only (Viibryd 08)

Viibryd 20 mg vilazodone HCl tablets label for a bottle of 30 tablets. The label includes storage instructions, manufacturer Allergan USA, Inc., and a note to dispense the accompanying medication guide. The product is Rx only and made in Taiwan.*

FDA Label Image

Ndc 0456-1140-30viibrydvilazodone Hcitablets30 Tablets40 mgrx Only (Viibryd 09)

Viibryd 40 mg tablets label showing product strength and active ingredient vilazodone hydrochloride. The label indicates a package size of 30 tablets, distributed by Allergan USA, Inc. It includes storage instructions and dosage guidance to refer to the medication guide. The NDC number 0456-1140-30 is also visible.*

FDA Label Image

Principal Display Panelndc 0456-1100-31viibrydvilazodone Hci Tablets10 mgdays 1-720 mgdays 8-1440 mgdays 15-30rx Only (Viibryd 0a)

Packaging label for Viibryd (vilazodone HCl) tablets in strengths of 10 mg, 20 mg, and 40 mg. The label indicates a 30-day treatment supply, including 7 tablets of 10 mg, 7 tablets of 20 mg, and 16 tablets of 40 mg. The panels show dosage instructions with colored sections for days 1-7, 8-14, and 15-30. Viibryd is labeled by Allergan, Inc.*

FDA Label Image

Principal Display Panelndc 0456-1101-30viibrydvilazodone Hci Tablets10 mgdays 1-720 mgdays 8-30rx Only (Viibryd 0b)

Packaging label for Viibryd (vilazodone HCl) tablets Starter Pack from Allergan, Inc. The label shows available strengths of 10 mg and 20 mg tablets, with directions indicating a dose escalation schedule from 10 mg (Days 1-7) to 20 mg (Days 8-30). The packaging is primarily green and white with pink highlights for dosage information and includes patient instructions and a space for patient name and holder information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.